ClinicalTrials.gov
ClinicalTrials.gov Menu

The Safety and Efficacy of Recombinant Human Prolactin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00438490
Recruitment Status : Completed
First Posted : February 22, 2007
Results First Posted : April 18, 2013
Last Update Posted : January 3, 2018
Sponsor:
Information provided by (Responsible Party):
Corrine Welt, Massachusetts General Hospital

Brief Summary:
Medications used to increase breast milk production increase prolactin secretion, the main hormone of lactation. There are no FDA approved medications used to improve breast feeding, but metoclopramide is used off-label and can have intolerable side effects. We examined the biological activity and safety of recombinant human prolactin (r-hPRL) as a potential medication to augment lactation. In this study, the effect of r-hPRL on breast milk production in women who did not recently deliver a baby and its effect on the bones and menstrual cycle were tested.

Condition or disease Intervention/treatment Phase
Healthy Drug: Recombinant Human Prolactin Phase 2

Detailed Description:
There are no FDA approved medications in the U.S. to augment lactation. Metoclopramide is used off-label but can have intolerable side effects. We examined the biological activity and safety of recombinant human prolactin (r-hPRL) as preliminary data for its use to augment lactation. Healthy, non-postpartum women (n=21) with regular menstrual cycles underwent a 7 day randomized, double-blind, placebo-controlled trial of r-hPRL. Galactorrhea, markers of bone turnover, calcium homeostasis and gonadal function were measured and side effects recorded.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Recombinant Human Prolactin Efficacy and Safety
Study Start Date : April 2002
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Prolactin
U.S. FDA Resources

Arm Intervention/treatment
Experimental: recombinant human prolactin
Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
Drug: Recombinant Human Prolactin
Placebo Comparator: Placebo
Normal saline placebo subcutaneous injection
Drug: Recombinant Human Prolactin



Primary Outcome Measures :
  1. Galactorrhea [ Time Frame: 7 days ]
    Galactorrhea is breast milk production.


Secondary Outcome Measures :
  1. N-telopeptide [ Time Frame: 7 days ]
  2. Menstrual Cycle Length [ Time Frame: 28 days ]
  3. Estradiol [ Time Frame: 7 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Healthy Subjects will meet the following criteria:

  1. 18 to 40 years of age
  2. Normal weight (BMI 17 to £ 30 kg/m2)
  3. Good general health
  4. On no medications for at least 3 months before the study
  5. Regular menstrual cycles every 25-35 days with ovulation documented by a luteal phase progesterone level
  6. No evidence of androgen excess
  7. Normal TSH, prolactin and hematocrit
  8. No current interest in conception
  9. No history of osteoporosis
  10. No use of medications known to affect bone turnover
  11. No alcoholism
  12. No smoking
  13. No history of medical problems or treatment known to affect bone turnover.

Exclusion Criteria:

Subjects will be excluded for pregnancy or evidence of breast masses.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00438490


Locations
United States, Massachusetts
Corrine Welt
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Corrine K. Welt, MD Massachusetts General Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Corrine Welt, Associate Professor of Medicine, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00438490     History of Changes
Other Study ID Numbers: 2001-P-001057
First Posted: February 22, 2007    Key Record Dates
Results First Posted: April 18, 2013
Last Update Posted: January 3, 2018
Last Verified: December 2017

Keywords provided by Corrine Welt, Massachusetts General Hospital:
galactorrhea
prolactin
bone turnover
menstrual cycle
Control Groups
Women